News

Australia medical regulator approves AstraZeneca name change

Published

4 years ago

August 19, 2021

Australia’s regulatory authority has approved a name change for the COVID-19 vaccine AstraZeneca, which will now be known as Vaxzevria.

The Therapeutic Goods Administration known in short as the TGA officially approved the name change in an effort to bring the naming conventions of the vaccine in line with the European Union and Canada.

FILE PHOTO: A test tube labelled “vaccine” in front of an AstraZeneca logo in this illustration taken, September 9, 2020. REUTERS/Dado Ruvic/Illustration

A change of name is the only change made to the vaccine

All other aspects – including ingredients, dosage, quality control and application – remain unchanged.

The Department of Health stated that the new name change is expected to “alleviate confusion” and to clarify that the vaccine produced by CSL and Seqirus in Melbourne is the same one that is produced internationally, such as in Belgium.

The name change will help facilitate international recognition for Australians who received the AstraZeneca vaccine.

News

Tech stocks on edge ahead of Nvidia

Nvidia’s earnings report could impact tech sector trends, prompting analysis of profit-taking versus deeper market concerns.

Published

7 hours ago

November 19, 2025

ticker NEWS

Nvidia’s earnings report could impact tech sector trends, prompting analysis of profit-taking versus deeper market concerns.

With Nvidia’s crucial earnings on deck, expectations are sky-high and the outcome could set the tone for the entire tech sector.

Chris Weston from Pepperstone breaks down whether this rotation signals simple profit-taking or deeper market concerns.

#TechStocks #Nvidia #Markets #Investing #FinanceNews

News

U.S. House forces release of Epstein files after Trump shift

House votes to release Epstein files after Trump’s stance shift, as victims rally and Senate vote approaches. #EpsteinFiles

Published

7 hours ago

November 19, 2025

ticker NEWS

House votes to release Epstein files after Trump’s stance shift, as victims rally and Senate vote approaches. #EpsteinFiles

The U.S. House has overwhelmingly voted to mandate the release of Justice Department files tied to Jeffrey Epstein, following a sudden shift in stance from President Donald Trump.

Victims rallied outside the Capitol as bipartisan criticism intensifies and the resolution heads to a swift Senate vote.

#EpsteinFiles #USPolitics #BreakingNews #Congress #Trump

News

Trump’s approval rating hits lowest point amid concerns

Trump’s approval plummets to 38% amid cost of living concerns and Epstein files backlash

Published

8 hours ago

November 19, 2025

ticker NEWS

Trump’s approval plummets to 38% amid cost of living concerns and Epstein files backlash

In Short:
– Trump’s approval rating has dropped to 38% due to concerns over costs and the Epstein investigation.
– Only 26% of Americans approve of Trump’s handling of everyday expenses amidst rising inflation.

A recent Reuters/Ipsos poll indicates U.S. President Donald Trump’s approval rating has dropped to 38%, marking the lowest level since his return to power. Dissatisfaction stems from rising living costs and concerns regarding the investigation into Jeffrey Epstein.The four-day poll, concluding on November 18, reveals only 26% of Americans approve of Trump’s management of everyday expenses. Increasing public concern regarding inflation has further eroded support. The Republican-controlled House recently passed a measure to release Justice Department files on Epstein, an issue Trump initially resisted but later supported.

Poll findings show Trump’s overall approval has declined two points since early November. He began his second term with a 47% approval rating, now nearing lows seen during his first term. Biden’s approval fell as low as 35%, reflective of economic discontent.

Republican Support Wanes

Trump’s approval rating among Republican voters is now 82%, a decrease from 87% earlier this month. The perception that he is not adequately addressing living costs is a significant concern, contributing to reduced popularity among constituents. Notably, only 20% approve of Trump’s handling of the Epstein case, with 70% believing the government is withholding information.

Trump’s economic strategy, which included tax increases on imports, has been criticized for contributing to rising prices. As midterm elections approach, his declining popularity may pose challenges for Republican candidates in upcoming races.